Enavate Sciences GP, LLC
Annual return '25
+91.7%
SPY '25
+17.7%
Alpha
+74.0ptsvs SPY
Invested
$351.5M
Holdings
7
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 94%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$SION
SIONNA THERAPEUTICS INC
Q1 2025: New position (2.48M shares)
28.3%
02
$IMNM
IMMUNOME INC
Q1 2025: Increased +37.1% (3.48M → 4.77M shares)
22.5%
03
$ZBIO
ZENAS BIOPHARMA INC
Q4 2024: New position (3.76M shares)
21.8%
04
$CMPX
COMPASS THERAPEUTICS INC
Q4 2024: New position (7.79M shares)
11.7%
05
$BBOT
BRIDGEBIO ONCOLOGY THERAPEUT
Q3 2025: New position (2.63M shares)
6.7%
06
$UPB
UPSTREAM BIO INC
Q4 2024: New position (2.46M shares)
6.3%
07
$CAMP
CAMP4 THERAPEUTICS CORP
Q4 2024: New position (3.79M shares)
2.7%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 04:25 UTC.